Emma Walmsley, GlaxoSmithKline (GSK) chief, says concerns over her leadership are unfounded and has labelled herself as a “change agent” seeking to reform the UK-based pharmaceutical giant following the spin-off of its consumer health division reports Financial Times.
Walmsley unveiled her plans for the fund this week following pressure from US-based hedge fund Elliott Management. Walmsley set the target of £33bn in sales by the end of 2031 and further said she “refused to be distracted” by questions surrounding her leadership style.
Despite questions around whether she could lead GSK because of her background in consumer health, she drove home the point that she was a “business leader” and remained “excited” about the future of the company.
This story is part of the Financial Times subscription – to read more, please subscribe.
